The U.S. Food and Drug Administration cleared the SpectraShield 9500 N95 surgical respirator, a device that kills 99.99 percent of three different kinds of bacteria when exposed to its outer surface.
The FDA has cleared the SpectraShield as a single-use, N95 surgical respirator for use in healthcare settings by healthcare personnel to protect against microorganisms, body fluids and particulate material.
Data from laboratory tests demonstrated that the respirator is effective against the following bacteria: Streptococcus pyogenes, methicillin-resistant Staphylococcus aureus (MRSA) and Haemophilus influenzae.
"The SpectraShield 9500 N95 anti-bacterial surgical respirator may reduce the risk of exposure to specific bacterial agents during medical emergencies," says Elizabeth Claverie-Williams, branch chief of Infection Control Devices at the FDA's Center for Devices and Radiological Health.
N95 surgical respirators are different than regular facemasks, which are designed to help block large-particle droplets, splashes, sprays, or splatter that may contain viruses and bacteria from reaching the mouth and nose.
While a regular facemask may be effective in blocking splashes and large-particle droplets, it does not filter or block tiny particles that may be transmitted by coughs, sneezes, or certain medical procedures. Regular facemasks also do not provide complete protection from germs and other contaminants because of the loose fit between the surface and the face.
The N95 designation means that the respirator blocks at least 95 percent of very small particles when subjected to careful testing. If properly fitted, the capabilities of N95 respirators exceed those of regular facemasks. Even a properly fitted N95 respirator, however, does not eliminate the risk of infection, illness, or death.
N95 surgical respirators cleared by the FDA for use in healthcare settings, including the SpectraShield 9500 N95 surgical respirator, have also been evaluated by the National Institute for Occupational Safety and Health, part of the Centers for Disease Control and Prevention.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies
Breaking the Cycle: Long COVID's Impact and the Urgent Need for Preventative Measures
November 15th 2024Masking, clean air, and vaccinations are essential in combating COVID-19 and preventing long-term impacts, as evidence mounts of long COVID's significant economic, cognitive, and behavioral effects.
The Critical Role of Rapid Diagnostics in Antibiotic Stewardship
November 6th 2024Rapid diagnostics enhance patient outcomes by enabling prompt, targeted treatments, reducing inappropriate antibiotic use, and combating antimicrobial resistance through informed clinical decisions and stewardship programs.